The role of multipotent cancer associated fibroblasts in hepatocarcinogenesis

BMC Cancer

Volumn 15, Issue 1, 2015, Pages

  Sukowati, Caecilia Hapsari Ceriapuri ^a,b   Anfuso, Beatrice ^b   Crocé, Lory Saveria ^a,b   Tiribelli, Claudio ^a,b  

^a UNIVERSITY OF TRIESTE   (Italy)

^b Fondazione Italiana Fegato (Italian Liver Foundation)   (Italy)

Author keywords

Cancer stem cells; Cancer associated fibroblasts; Hepatocellular carcinoma; Microenvironment; Stem cells; Stroma

Indexed keywords

ALPHA SMOOTH MUSCLE ACTIN; CD133 ANTIGEN; CD34 ANTIGEN; CD45 ANTIGEN; HERMES ANTIGEN; SEPRASE; STEM CELL FACTOR RECEPTOR; THY 1 ANTIGEN; TRANSFORMING GROWTH FACTOR BETA1; VIMENTIN;

ADIPOCYTE; AGED; ANCHORAGE INDEPENDENT GROWTH; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER GROWTH; CELL ASSAY; CELL CULTURE; CELL FUNCTION; CELL ISOLATION; CELL STIMULATION; CELL TRANSDIFFERENTIATION; CLINICAL ARTICLE; COCULTURE; DNA SEQUENCE; FEMALE; FIBROBLAST; FLOW CYTOMETRY; GENE EXPRESSION; HEPATOCELLULAR CARCINOMA CELL LINE; HUH 7 CELL LINE; HUMAN; HUMAN CELL; HUMAN TISSUE; JHH 6 CELL LINE; LIVER CARCINOGENESIS; LIVER CELL CARCINOMA; MALE; METASTASIS; MOUSE; MULTIPOTENT CANCER ASSOCIATED FIBROBLAST; NONHUMAN; OSTEOBLAST; PANCREAS CELL; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; TUMOR XENOGRAFT; UPREGULATION; ANIMAL; CANCER STEM CELL; CARCINOMA, HEPATOCELLULAR; CELL TRANSFORMATION; DISEASE MODEL; IMMUNOPHENOTYPING; LIVER NEOPLASMS; METABOLISM; PATHOLOGY; PHENOTYPE; TUMOR CELL LINE; VERY ELDERLY; XENOGRAFT;

AGED; AGED, 80 AND OVER; ANIMALS; CARCINOMA, HEPATOCELLULAR; CELL LINE, TUMOR; CELL TRANSDIFFERENTIATION; CELL TRANSFORMATION, NEOPLASTIC; COCULTURE TECHNIQUES; DISEASE MODELS, ANIMAL; FEMALE; FIBROBLASTS; HETEROGRAFTS; HUMANS; IMMUNOPHENOTYPING; LIVER NEOPLASMS; MALE; MICE; NEOPLASTIC STEM CELLS; PHENOTYPE;

EID: 84926299225     PISSN: None     EISSN: 14712407     Source Type: Journal    
DOI: 10.1186/s12885-015-1196-y     Document Type: Article

References (18)

1. Bray F, Ren J-S, Masuyer E, Ferlay J. Global estimates of cancer prevalence for 27 sites in the adult population in 2008. Int J Cancer. 2013;132:1133-45.
2. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007;132:2557-76.
3. Fransvea E, Mazzocca A, Antonaci S, Giannelli G. Targeting transforming growth factor (TGF)-betaRI inhibits activation of beta1 integrin and blocks vascular invasion in hepatocellular carcinoma. Hepatol Baltim Md. 2009;49:839-50.
4. Mazzocca A, Fransvea E, Dituri F, Lupo L, Antonaci S, Giannelli G. Down-regulation of connective tissue growth factor by inhibition of transforming growth factor beta blocks the tumor-stroma cross-talk and tumor progression in hepatocellular carcinoma. Hepatol Baltim Md. 2010;51:523-34.
5. Mazzocca A, Dituri F, Lupo L, Quaranta M, Antonaci S, Giannelli G. Tumor-secreted lysophostatidic acid accelerates hepatocellular carcinoma progression by promoting differentiation of peritumoral fibroblasts in myofibroblasts. Hepatol Baltim Md. 2011;54:920-30.
6. Cesselli D, Beltrami AP, Poz A, Marzinotto S, Comisso E, Bergamin N, et al. Role of tumor associated fibroblasts in human liver regeneration, cirrhosis, and cancer. Int J Hepatol. 2011;2011:120925.
7. Bustin SA, Benes V, Garson JA, Hellemans J, Huggett J, Kubista M, et al. The MIQE guidelines: minimum information for publication of quantitative real-time PCR experiments. Clin Chem. 2009;55:611-22.
8. Pfaffl MW. A new mathematical model for relative quantification in real-time RT-PCR. Nucleic Acids Res. 2001;29:e45.
9. Tichopad A, Didier A, Pfaffl MW. Inhibition of real-time RT-PCR quantification due to tissue-specific contaminants. Mol Cell Probes. 2004;18:45-50.
10. Ma S, Chan K-W, Hu L, Lee TK-W, Wo JY-H, Ng IO-L, et al. Identification and characterization of tumorigenic liver cancer stem/progenitor cells. Gastroenterology. 2007;132:2542-56.
11. Suetsugu A, Nagaki M, Aoki H, Motohashi T, Kunisada T, Moriwaki H. Characterization of CD133+ hepatocellular carcinoma cells as cancer stem/progenitor cells. Biochem Biophys Res Commun. 2006;351:820-4.
12. Herrera MB, Bruno S, Buttiglieri S, Tetta C, Gatti S, Deregibus MC, et al. Isolation and characterization of a stem cell population from adult human liver. Stem Cells Dayt Ohio. 2006;24:2840-50.
13. Yang L, Li S, Hatch H, Ahrens K, Cornelius JG, Petersen BE, et al. In vitro trans-differentiation of adult hepatic stem cells into pancreatic endocrine hormone-producing cells. Proc Natl Acad Sci USA. 2002;99:8078-83.
14. Dominici M, Le Blanc K, Mueller I, Slaper-Cortenbach I, Marini F, Krause D, et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy. 2006;8:315-7.
15. Horwitz EM, Le Blanc K, Dominici M, Mueller I, Slaper-Cortenbach I, Marini FC, et al. International society for cellular therapy: clarification of the nomenclature for MSC: the international society for cellular therapy position statement. Cytotherapy. 2005;7:393-5.
16. Yang ZF, Ho DW, Ng MN, Lau CK, Yu WC, Ngai P, et al. Significance of CD90+ cancer stem cells in human liver cancer. Cancer Cell. 2008;13:153-66.
17. Sukowati CHC, Anfuso B, Torre G, Francalanci P, Crocè LS, Tiribelli C. The expression of CD90/Thy-1 in hepatocellular carcinoma: an in vivo and in vitro study. PLoS One. 2013;8:e76830.
18. Yamashita T, Honda M, Nakamoto Y, Baba M, Nio K, Hara Y, et al. Discrete nature of EpCAM+ and CD90+ cancer stem cells in human hepatocellular carcinoma. Hepatol Baltim Md. 2013;57:1484-97.